exp date isn't null, but text field is
Distal Intestinal Obstruction Syndrome (DIOS) , adhesional obstruction and severe constipation management in children with cystic fibrosis RHC Glasgow
Patients with Cystic Fibrosis usually require to take pancreatic enzyme supplements with all foods in order to digest fat and protein in their diet. Even with optimal pancreatic enzyme replacement therapy, only up to 85% of all ingested fat may be successfully absorbed. Occasionally, stool fat content will increase over time, resulting in stool accumulation –in the distal ileum presenting as DIOS, or more generally throughout the colon presenting as severe constipation. Patients who are pancreatic sufficient may also present in this way. Children with cystic fibrosis who have had previous surgery (particularly a laparotomy in the neonatal period for meconium ileus) may have complications related to intraperitoneal adhesions.
Constipation, DIOS and adhesional obstruction may occur in children with Cystic Fibrosis, and the presentation may be similar with degrees of abdominal pain, abdominal distension and obstipation. With DIOS and adhesional obstruction, there may be an acute onset of symptoms versus a more gradual onset of symptoms in constipation.
In practice, the differential diagnosis of mild incomplete DIOS versus severe constipation may not always be possible to make clinically. Although an abdominal X-ray may help to clarify this by showing faecal accumulation predominantly in the right flank in DIOS, imaging may not be required as initial management of these conditions is similar 1,2.
However if there is concern that there may be complete intestinal obstruction - especially in children who have had previous abdominal surgery - eg a history of severe or worsening abdominal pain and / or vomiting – especially bilious - a plain abdominal x-ray (AXR) should be requested early. Dilated bowel loops +/- Intestinal fluid levels may support a diagnosis of complete DIOS with obstruction, or adhesional obstruction.
DIOS incidence varies widely (paediatric lifetime prevalence of ~8%) but it mostly affects those with pancreatic insufficiency. The pathophysiology is not fully understood, but there may be multiple contributory factors including:
ESPGHAN Working Group Definition of DIOS in CF 3
CRITERIA |
COMPLETE / OBSTRUCTED DIOS |
INCOMPLETE DIOS |
|||
1 |
Complete intestinal obstruction as evidenced by vomiting of bilious material and/or fluid levels in small intestine on an abdominal radiograph |
√ |
|||
2 |
Faecal mass in ileo-caecum |
√ |
√ |
||
3 |
Abdominal pain and/or distension |
√ |
√ |
Incomplete DIOS - Mild / Severe
DIOS is associated with relatively acute onset of symptoms (days rather than weeks) .Thick faecal material accumulates in the terminal ileum leading to partial obstruction in incomplete DIOS. Symptoms may be mild or severe and include mild to moderate intermittent, peri-umbilical and/or right lower quadrant abdominal pain with nausea. There may be a palpable mass in the RIF. Children who have had previous surgery (particularly a laparotomy in the neonatal period for meconium ileus) may have complications related to intraperitoneal adhesions – close monitoring for developing signs of complete obstruction is required.
Management of Mild / Severe Incomplete DIOS
Management is step-wise and will depend on severity of symptoms and response to treatment Stages 1-3.
If there is any concern that complete bowel obstruction has occurred a plain abdominal x-ray (AXR) is required.
INCOMPLETE DIOS- MANAGEMENT |
||||
Symptoms / Signs |
Abdominal pain predominantly right lower quadrant with abdominal fullness +/-palpable mass right iliac fossa. |
|||
Mild |
Stage 1 Ensure adequate hydration. Faecal Disimpaction Protocol for up to 5 days with review. |
Stage 2 If symptoms persist despite Stage 1 |
If symptoms do not respond to Stage 1&2 or patient cannot tolerate oral Gastrografin -treat as Severe Incomplete DIOS – Stage 3. At all Stages, monitor for symptoms of Complete / Obstructed DIOS eg frequent or worsening vomiting (often bilious), worsening abdominal pain. |
|
STAGE 1&2 Mild Incomplete DIOS Only- Oral N-acetylcysteine (NAC) – disulphide bond breaker may be added to treatment- see Formulary |
||||
Severe Incomplete DIOS |
Stage 3 |
Monitor for symptoms of Complete /Obstructed DIOS eg frequent or worsening vomiting (often bilious), worsening abdominal pain. |
Complete / Obstructed DIOS
Complete/ Obstructed DIOS is characterised by abdominal distension, worsening abdominal pain (often colicky), frequent or worsening vomiting –often bilious - and bowel loop dilatation +/- fluid levels on AXR. Complete DIOS is rare in children, but a surgical opinion should be sought early and AXR requested if this is suspected or there is doubt about the differential diagnosis eg complex / complicated case due to previous abdominal surgery. In particular, signs of intestinal ischaemia should prompt immediate surgical referral. These include tachycardia, pyrexia, abdominal tenderness on palpation or percussion, and raised inflammatory markers.
COMPLETE DIOS – MANAGEMENT |
|||
Symptoms / Signs |
Abdominal pain -often colicky |
||
Management- Complete DIOS |
Seek early Surgical advice. |
NG tube is needed to empty the stomach and prevent bilious aspiration. Establish IV fluids. |
Regular assessment by on-call surgical team with consideration of early operative management |
Constipation may occur over a period of time (weeks rather than days) and present with a history of generalized abdominal pain and infrequent, hard stools. Clinical examination may reveal faecal masses which are generally felt in the left iliac fossa. Vomiting is rare and non-bilious.
Mild constipation can be managed with regular laxatives. If constipation is prolonged or severe the GGC Paediatric Disimpaction protocol may be required. There should be frequent review of the patient’s progress at home and re-assessment with AXR if signs of complete obstruction become evident.
GGC Paediatric Disimpaction Protocol
Paediatric Movicol-
If disimpaction not achieved by 2 weeks, add a stimulant laxative eg Senna. If Movicol is not tolerated, use Lactulose and Senna for disimpaction
Further Management
Following treatment for DIOS or Severe Constipation, Movicol Paediatric should be prescribed for ongoing home use:
Child 1–11 months
0.5–1 sachet daily.
Child 1 year
1 sachet daily, adjust dose to produce regular soft stools; maximum 4 sachets per day.
Child 2–5 years
1 sachet daily, adjust dose to produce regular soft stools; maximum 4 sachets per day.
Child 6–11 years
2 sachets daily, adjust dose to produce regular soft stools; maximum 4 sachets per day.
Oral regular paracetamol - doses as per BNFC
For severe pain consider IV paracetamol for 24-48 hours- doses as per BNFC.
Avoid/stop all opioid analgesia
Distal intestinal obstruction syndrome in children with cystic fibrosis
By mouth
Child 1–23 months
15–30 mL for 1 dose.
Child (body-weight 15–25 kg)
50 mL for 1 dose.
Child (body-weight 26 kg and above)
100 mL for 1 dose.
Directions for administration
Intravenous prehydration is essential in neonates and infants. Fluid intake should be encouraged for 3 hours after administration.
By mouth
Distal intestinal obstruction syndrome
By mouth, or by nasogastric tube, or by gastrostomy tube
Child 1–17 years
10 mL/kilogram/hour for 30 minutes, then increased to 20 mL/kilogram/hour for 30 minutes, then increased if tolerated to 25 mL/kilogram/hour, max. 100 mL/kg (or 4 litres) over 4 hours, repeat 4 hour treatment if necessary.
Directions for administration
1 sachet should be reconstituted with 1 litre of water.
Flavouring such as clear fruit cordials may be added if required.
After reconstitution the solution should be kept in a refrigerator and discarded if unused after 24 hours.
Oral N-acetylcysteine – Disulphide bond breaker.
The 200mg/ml injection can be given orally and should be mixed with water, orange juice, blackcurrant juice or cola to a concentration of 50mg/ml.
Alternatively, 200mg sachets or 600mg tablets are available.
For larger doses consider the use of the IV preparation for oral administration to reduce the burden of volume
1. Carla Colombo, Helmut Ellemunter, Roderick Houwen, Anne Munck, Chris Taylor, Michael Wilschanski on behalf of the ECFS. Guidelines for the diagnosis and management of distal intestinal obstruction syndrome in cystic fibrosis patients. Journal of Cystic Fibrosis, Volume 10 Suppl 2 (2011) S24–S28.
Last reviewed: 22 March 2021
Next review: 01 March 2023
Author(s): Dr Jane Wilkinson, Dr Rachel Tayler, Mr Gregor Walker, Dr Tom Savage, Susan Kafka, Julie Crocker
Version: 2
Approved By: Paediatric Drugs & Therapeutics Committee